Vimarsana
Biggest News Aggregation in the World

Page 3 - Jonathan Silverberg News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jonathan Silverberg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jonathan Silverberg Today - Breaking & Trending Today

Galderma to Showcase Latest Updates From Its Broad Innovative and Leading Dermatology Portfolio at the 2024 American Academy of Dermatology Annual Meeting - Vimarsana News

Galderma to Showcase Latest Updates From Its Broad Innovative and Leading Dermatology Portfolio at the 2024 American Academy of Dermatology Annual Meeting

Galderma the pureplay dermatology category leader will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology AAD Annual Meeting from March 812 2024 highlighting its broad innovative and leading dermatology portfolio.

Dr Jonathan Silverberg Lists Which Patients With AD Benefit Most From JAK Inhibitors - Vimarsana News

Dr Jonathan Silverberg Lists Which Patients With AD Benefit Most From JAK Inhibitors

Jonathan Silverberg, MD, PhD, MPH, of George Washington University School of Medicine and Health Sciences, explains the benefits of using Janus kinase (JAK) inhibitors to treat patients with atopic dermatitis (AD).

Source: ajmc.com
ICYMI: Highlights From RAD 2023 - Vimarsana News

ICYMI: Highlights From RAD 2023

Our top coverage from this year’s Revolutionizing Atopic Dermatitis (RAD) conference highlighted the evolving therapy landscape for patients with AD.

Source: ajmc.com
Clinical Challenges: Atopic Dermatitis in Infants - Vimarsana News

Clinical Challenges: Atopic Dermatitis in Infants

Studies show that early disease control lowers risk of developing other atopic morbidities

Nektar Therapeutics (NASDAQ:NKTR) Q3 2023 Earnings Call Transcript - Vimarsana News

Nektar Therapeutics (NASDAQ:NKTR) Q3 2023 Earnings Call Transcript

Operator: Good day and thank you for standing by. Welcome to the Nektar Therapeutics Third Quarter 2023 Financial Results Conference Call.